Last updated: May 25, 2026
Nadolol Suppliers: Who Manufactures It, Who Sells It, and What Inputs Power Production
Nadolol is a generic small-molecule beta blocker supplied globally through branded and contract manufacturing channels. Publicly visible supply is dominated by generic manufacturers and API/DFD (drug product intermediates and dosage-form developers) operating under multiple markets. A complete, supplier-level map by API source, finished-dose OEM, and distribution partner cannot be produced from the information available here.
What companies supply nadolol drug product (tablets) in the US?
Nadolol marketed in the US is typically supplied as generic tablets under multiple NDCs through FDA-registered manufacturers and their labelers. The authoritative “who makes it” layer for each strength is the FDA Orange Book listing for nadolol products and the manufacturers shown on the corresponding NDCs.
How do you identify nadolol finished-dose suppliers fast?
- Use the FDA Orange Book “Drug Product” section for nadolol (including each strength and dosage form).
- Match Orange Book listed “Applicant/Manufacturer” names to the NDC labeler and distribution chain shown in FDA’s NDC directory and wholesalers’ listings.
- Track changes using Orange Book “Patent/Exclusivity” history and labeler updates.
Who supplies nadolol API (active pharmaceutical ingredient)?
API supply for older beta blockers like nadolol is usually sourced from multiple international chemical/API manufacturers and sold through distributors and toll-manufacturing arrangements. The API supplier set for nadolol also shifts by product labeler due to qualification and CGMP auditing.
API sourcing patterns for nadolol
- Multi-supplier strategy: labelers qualify at least two API routes to manage lead times.
- Tolling: some US/EU labelers use contract API manufacture and only hold formulation and packaging ownership.
- Powder-grade control: nadolol API quality depends on polymorph/particle properties and impurity profiles, so labelers source to a defined spec set rather than only “chemical name.”
What excipients and intermediates are required to manufacture nadolol tablets?
Tablet supply depends on the dosage form, not just the API. Typical nadolol tablets require standard direct-compression or wet-granulation excipients. The exact bill of materials varies by generic manufacturer and strength.
Common manufacturing inputs (generic tablet context)
- Binders (for granules or tablet strength)
- Disintegrants (for tablet breakup)
- Lubricants and glidants (for flow and compression)
- Film coatings or seal coats (if applicable)
- Packaging components: PVC/PVDC-Alu blisters or HDPE bottles with desiccant where needed
Which nadolol suppliers dominate by geography and regulatory footprint?
Nadolol supply tends to concentrate among firms with broad FDA market coverage, an established ANDA/DMF pipeline, and supply continuity for older generics.
Geographic footprint
- US and EU: labelers and contract manufacturers under FDA/EMA-aligned CGMP
- India and China: API and intermediate production capacity, including DMF-led API qualification
- Global distributors: consolidation and regional stockholding to manage demand swings
What is the Orange Book status of nadolol products and how does it affect supply?
Orange Book status affects entry timing for generics and the ability to sustain multiple manufacturers on the same strength.
How Orange Book status influences supplier landscape
- If a brand or reference product has any unexpired patent or exclusivity, fewer ANDAs may be approved for the same strength/form.
- If patents have expired, more generic firms can list products, increasing supplier redundancy.
- Even after patent expiry, regulatory readiness (CGMP batch release, stability data, and impurity controls) drives which suppliers can scale.
Which companies are challenging or litigating nadolol generic entry?
Patent litigation and Paragraph IV challenges shape who supplies the market at launch and immediately after. For nadolol, litigation records must be tied to specific ANDAs, strengths, and filing years.
What to check for nadolol-specific litigation
- FDA ANDA history for nadolol strengths
- Court dockets and settlement announcements tied to specific Orange Book-listed patents
- 30/31/35 month stay periods linked to Paragraph IV filings
What patent estate strength impacts nadolol supplier count?
For older generics, patent estate strength typically declines over time, which increases supplier counts. Supplier diversification is also driven by manufacturing economics and API continuity.
Typical levers
- Remaining method-of-use, process, and impurity-control patents can limit certain manufacturing approaches.
- Formulation-specific patents can restrict film-coating or excipient systems if claimed.
- Supply chain dependence on specific impurity profiles can shrink qualified suppliers.
How do nadolol suppliers manage CGMP for API and tablet manufacture?
CGMP management is driven by impurity controls, analytical method validation, stability, and batch reproducibility.
Quality system expectations
- DMF or CEP alignment for API (where applicable)
- Controlled blending, drying, and milling (if tablet uses intermediate processing)
- Process validation and continued process verification for scale changes
- Container closure and stability management for multiple packaging configurations
What generic entry risks exist for nadolol suppliers?
Generic entry risk is lower for well-established, widely manufactured dosage strengths but can be material during transitions such as:
- API source changeovers
- facility ownership transfers
- scale-up after tech transfer
- compliance enforcement actions in major manufacturing hubs
Risk points specific to older beta blockers
- Tight impurity specs can constrain API suppliers
- Polymorph and particle attribute drift can disrupt compression performance and dissolution
- Lead-time volatility in API chemistry can cause supply interruptions
Nadolol supplier procurement checklist (for sourcing teams)
- Confirm strength, dosage form, and target regulatory market (US/EU).
- Verify the finished-dose manufacturer and NDC listing on FDA systems.
- Request: API CoA, tablet stability data, impurity profile, and batch release documentation.
- Validate change-control history for API and tablet process steps.
- Run packaging compatibility and humidity protection checks by region.
Key Takeaways
- Nadolol supply is dominated by multiple generic finished-dose manufacturers with additional API supply from qualified global chemical producers.
- The most reliable way to enumerate nadolol suppliers by strength is FDA Orange Book plus NDC directory mapping by labeler and applicant.
- Supplier count and manufacturing continuity track Orange Book patent status and facility qualification rather than only chemical availability.
FAQs
1) How do I find the manufacturer for a specific nadolol NDC?
Use the NDC directory to identify the labeler tied to the exact strength/form, then cross-check the Orange Book listing for the same product.
2) Who controls nadolol API quality for generic tablets?
The finished-dose applicant/manufacturer sets the specification and qualified supplier list; API quality is enforced via CoA and validated impurity/assay methods.
3) Why do nadolol tablet suppliers change over time?
Qualification cycles, DMF updates, CGMP performance, and API supply continuity drive changes in the qualified and commercially active supplier list.
4) Does nadolol have multiple tablet strengths with different suppliers?
Yes, supplier and labeler coverage often differs by strength due to stability, formulation, and manufacturing line allocation.
5) What documentation should a nadolol distributor request before contracting?
API and finished-dose CoAs, analytical methods and impurity profile reports, stability protocols and latest stability results, and batch release records for recent lots.
References
- U.S. Food and Drug Administration. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. FDA.
- U.S. Food and Drug Administration. NDC Directory. FDA.
